dimethyl[(4-{[(2-{[(Z)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine

• ChemBase ID: 72817
• Molecular Formular: C12H21N5O2S2
• Molecular Mass: 331.45744
• Monoisotopic Mass: 331.11366694
• SMILES: s1c(nc(c1)CSCCN/C(=C\[N+](=O)[O-])/NC)CN(C)C
• Canonical SMILES: CN/C(=C/[N+](=O)[O-])/NCCSCc1csc(n1)CN(C)C
• InChI: InChI=1S/C12H21N5O2S2/c1-13-11(6-17(18)19)14-4-5-20-8-10-9-21-12(15-10)7-16(2)3/h6,9,13-14H,4-5,7-8H2,1-3H3/b11-6-
• InChIKey: SGXXNSQHWDMGGP-WDZFZDKYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: dimethyl[(4-{[(2-{[(Z)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine
• IUPAC Traditional name: dimethyl[(4-{[(2-{[(Z)-1-(methylamino)-2-nitroethenyl]amino}ethyl)sulfanyl]methyl}-1,3-thiazol-2-yl)methyl]amine
• Synonyms: Tazac; Axid; Axid AR; Nizatidine

Database IDs

• CAS Number: 76963-41-2
• PubChem SID: 162037738
• PubChem CID: 5353831

CALCULATED PROPERTIES

• H Acceptors: 6
• H Donor: 2
• LogD (pH = 5.5): -0.5839727
• LogD (pH = 7.4): 0.65984267
• Log P: 0.76301336
• Molar Refractivity: 96.8422 cm^3
• Polarizability: 33.263428 Å^3
• Polar Surface Area: 86.01 Å^2
• Rotatable Bonds: 10
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S1890

Research Area: Metabolic Disease
Biological Activity:
Nizatidine is a histamine H2-receptor antagonist with and IC50 of 6.7 nM for AChE. [1] It inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). The relative anti-AChE potency was in the following order: neostigmine > nizatidine >cimetidine >> famotidine. The inhibition of AChE by nizatidine was noncompetitive, with a Ki value of 7.4 x 10 nM. Gastrointestinal (GI) motility was examined during the interdigestive state in dogs with chronically implanted force transducers. [2]

REFERENCES

• Ueki S et al. J Pharmacol Exp Ther. 1993 Jan;264